Phase II study of biweekly cetuximab therapy for unresectable colorectal cancer

Phase II study of biweekly cetuximab therapy for unresectable colorectal cancer - Phase II study of biweekly cetuximab therapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011361

Enrollment

Registered

2013-08-03

Start date

2013-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable colorectal cancer

Interventions

biweekly administration of cetuximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Eligible patients had to have a histologically verified adenocarcinoma of the colon and rectum. 2)Adequate bone marrow, liver, renal, and cardiac function 3)The patient with KRAS-wild type tumor

Exclusion criteria

Exclusion criteria: 1)other co-existing malignancy 2)severe concurrent medical orpsychiatric illness 3)patients were pregnant or lactating.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Adverse event Disease control rate Disease free survival	—

Countries

Japan

Contacts

Public ContactKiyoshi Maeda

Osaka City University Hospital Department of Surgical Oncology

m1378386@med.osaka-cu.ac.jp06-6645-3838

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026